nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Dactinomycin—testicular cancer	0.0987	0.207	CbGbCtD
Afatinib—ABCG2—Carboplatin—testicular cancer	0.0663	0.139	CbGbCtD
Afatinib—ABCG2—Cisplatin—testicular cancer	0.0567	0.119	CbGbCtD
Afatinib—ABCG2—Etoposide—testicular cancer	0.0557	0.117	CbGbCtD
Afatinib—ABCG2—Doxorubicin—testicular cancer	0.038	0.0795	CbGbCtD
Afatinib—ABCG2—Methotrexate—testicular cancer	0.0368	0.0771	CbGbCtD
Afatinib—ABCB1—Dactinomycin—testicular cancer	0.0356	0.0745	CbGbCtD
Afatinib—ABCB1—Vinblastine—testicular cancer	0.0223	0.0467	CbGbCtD
Afatinib—ABCB1—Cisplatin—testicular cancer	0.0204	0.0428	CbGbCtD
Afatinib—ABCB1—Etoposide—testicular cancer	0.0201	0.042	CbGbCtD
Afatinib—ABCB1—Doxorubicin—testicular cancer	0.0137	0.0287	CbGbCtD
Afatinib—ABCB1—Methotrexate—testicular cancer	0.0133	0.0278	CbGbCtD
Afatinib—Vandetanib—STK10—testicular cancer	0.00731	0.513	CrCbGaD
Afatinib—Gefitinib—STK10—testicular cancer	0.00694	0.487	CrCbGaD
Afatinib—ERBB2—embryo—testicular cancer	0.00648	0.0541	CbGeAlD
Afatinib—ERBB4—embryo—testicular cancer	0.00648	0.0541	CbGeAlD
Afatinib—HIPK4—gonad—testicular cancer	0.00642	0.0535	CbGeAlD
Afatinib—EPHA6—gonad—testicular cancer	0.00508	0.0423	CbGeAlD
Afatinib—PHKG2—gonad—testicular cancer	0.00489	0.0408	CbGeAlD
Afatinib—HIPK4—testis—testicular cancer	0.00463	0.0386	CbGeAlD
Afatinib—ERBB2—gonad—testicular cancer	0.0044	0.0367	CbGeAlD
Afatinib—DYRK1A—gonad—testicular cancer	0.00424	0.0353	CbGeAlD
Afatinib—PHKG2—female gonad—testicular cancer	0.00398	0.0332	CbGeAlD
Afatinib—EPHA6—testis—testicular cancer	0.00366	0.0305	CbGeAlD
Afatinib—ERBB2—female gonad—testicular cancer	0.00358	0.0298	CbGeAlD
Afatinib—PHKG2—testis—testicular cancer	0.00353	0.0294	CbGeAlD
Afatinib—DYRK1A—female gonad—testicular cancer	0.00344	0.0287	CbGeAlD
Afatinib—BLK—lymph node—testicular cancer	0.00335	0.028	CbGeAlD
Afatinib—ERBB2—testis—testicular cancer	0.00317	0.0264	CbGeAlD
Afatinib—ERBB4—testis—testicular cancer	0.00317	0.0264	CbGeAlD
Afatinib—DYRK1A—testis—testicular cancer	0.00305	0.0255	CbGeAlD
Afatinib—EGFR—female gonad—testicular cancer	0.00303	0.0253	CbGeAlD
Afatinib—ABL1—embryo—testicular cancer	0.00272	0.0226	CbGeAlD
Afatinib—EGFR—testis—testicular cancer	0.00269	0.0224	CbGeAlD
Afatinib—IRAK1—female gonad—testicular cancer	0.00267	0.0223	CbGeAlD
Afatinib—LCK—female gonad—testicular cancer	0.00261	0.0217	CbGeAlD
Afatinib—PHKG2—lymph node—testicular cancer	0.00256	0.0213	CbGeAlD
Afatinib—ABL1—seminal vesicle—testicular cancer	0.00255	0.0213	CbGeAlD
Afatinib—IRAK1—testis—testicular cancer	0.00237	0.0198	CbGeAlD
Afatinib—LCK—testis—testicular cancer	0.00231	0.0193	CbGeAlD
Afatinib—ERBB2—lymph node—testicular cancer	0.0023	0.0192	CbGeAlD
Afatinib—DYRK1A—lymph node—testicular cancer	0.00221	0.0184	CbGeAlD
Afatinib—EGFR—lymph node—testicular cancer	0.00195	0.0162	CbGeAlD
Afatinib—ABL1—gonad—testicular cancer	0.00184	0.0154	CbGeAlD
Afatinib—IRAK1—lymph node—testicular cancer	0.00172	0.0143	CbGeAlD
Afatinib—LCK—lymph node—testicular cancer	0.00168	0.014	CbGeAlD
Afatinib—ABCG2—seminal vesicle—testicular cancer	0.00161	0.0134	CbGeAlD
Afatinib—ABL1—female gonad—testicular cancer	0.0015	0.0125	CbGeAlD
Afatinib—ABL1—testis—testicular cancer	0.00133	0.0111	CbGeAlD
Afatinib—ERBB2—Podofilox—Etoposide—testicular cancer	0.0011	0.122	CbGdCrCtD
Afatinib—ABL1—lymph node—testicular cancer	0.000963	0.00803	CbGeAlD
Afatinib—ABCG2—female gonad—testicular cancer	0.000945	0.00788	CbGeAlD
Afatinib—ABCB1—embryo—testicular cancer	0.000845	0.00704	CbGeAlD
Afatinib—ABCG2—testis—testicular cancer	0.000838	0.00699	CbGeAlD
Afatinib—ABCB1—seminal vesicle—testicular cancer	0.000793	0.00661	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Epirubicin—testicular cancer	0.000749	0.083	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—testicular cancer	0.000749	0.083	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—testicular cancer	0.000749	0.083	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—testicular cancer	0.000693	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—testicular cancer	0.000693	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—testicular cancer	0.000693	0.0768	CbGdCrCtD
Afatinib—ABCG2—lymph node—testicular cancer	0.000607	0.00506	CbGeAlD
Afatinib—ERBB2—Doxorubicin—Epirubicin—testicular cancer	0.000576	0.0639	CbGdCrCtD
Afatinib—ABCB1—gonad—testicular cancer	0.000573	0.00478	CbGeAlD
Afatinib—ERBB2—Epirubicin—Doxorubicin—testicular cancer	0.000533	0.0591	CbGdCrCtD
Afatinib—Urethral disorder—Cisplatin—testicular cancer	0.000531	0.00259	CcSEcCtD
Afatinib—Constipation—Vinblastine—testicular cancer	0.000529	0.00258	CcSEcCtD
Afatinib—Hepatobiliary disease—Etoposide—testicular cancer	0.000523	0.00255	CcSEcCtD
Afatinib—Infection—Bleomycin—testicular cancer	0.000519	0.00254	CcSEcCtD
Afatinib—Sepsis—Methotrexate—testicular cancer	0.000514	0.00251	CcSEcCtD
Afatinib—Dry eye—Epirubicin—testicular cancer	0.000512	0.0025	CcSEcCtD
Afatinib—Eye disorder—Cisplatin—testicular cancer	0.000507	0.00247	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—testicular cancer	0.000501	0.00245	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—testicular cancer	0.000501	0.00245	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—testicular cancer	0.000501	0.00245	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—testicular cancer	0.000495	0.00242	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—testicular cancer	0.00049	0.00239	CcSEcCtD
Afatinib—Mediastinal disorder—Cisplatin—testicular cancer	0.000489	0.00239	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—testicular cancer	0.000487	0.00238	CcSEcCtD
Afatinib—Asthenia—Chlorambucil—testicular cancer	0.000485	0.00237	CcSEcCtD
Afatinib—Infection—Dactinomycin—testicular cancer	0.000484	0.00236	CcSEcCtD
Afatinib—Sepsis—Epirubicin—testicular cancer	0.000481	0.00235	CcSEcCtD
Afatinib—Alopecia—Cisplatin—testicular cancer	0.000479	0.00234	CcSEcCtD
Afatinib—Pruritus—Chlorambucil—testicular cancer	0.000478	0.00233	CcSEcCtD
Afatinib—Cough—Ifosfamide—testicular cancer	0.000478	0.00233	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—testicular cancer	0.000474	0.00231	CcSEcCtD
Afatinib—Malnutrition—Cisplatin—testicular cancer	0.000472	0.0023	CcSEcCtD
Afatinib—Dyspnoea—Bleomycin—testicular cancer	0.000466	0.00228	CcSEcCtD
Afatinib—ABCB1—female gonad—testicular cancer	0.000466	0.00388	CbGeAlD
Afatinib—Eye disorder—Etoposide—testicular cancer	0.000464	0.00227	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—testicular cancer	0.000464	0.00226	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—testicular cancer	0.000464	0.00226	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000463	0.00226	CcSEcCtD
Afatinib—Diarrhoea—Chlorambucil—testicular cancer	0.000462	0.00226	CcSEcCtD
Afatinib—Decreased appetite—Bleomycin—testicular cancer	0.000454	0.00222	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—testicular cancer	0.000454	0.00222	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—testicular cancer	0.000448	0.00219	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—testicular cancer	0.000445	0.00217	CcSEcCtD
Afatinib—Asthenia—Vinblastine—testicular cancer	0.000444	0.00217	CcSEcCtD
Afatinib—Infection—Ifosfamide—testicular cancer	0.000444	0.00217	CcSEcCtD
Afatinib—Alopecia—Etoposide—testicular cancer	0.000439	0.00214	CcSEcCtD
Afatinib—Nervous system disorder—Ifosfamide—testicular cancer	0.000438	0.00214	CcSEcCtD
Afatinib—Skin disorder—Ifosfamide—testicular cancer	0.000434	0.00212	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.00043	0.0477	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.00043	0.0477	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.00043	0.0477	CbGdCrCtD
Afatinib—Vomiting—Chlorambucil—testicular cancer	0.000429	0.0021	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—testicular cancer	0.000424	0.00207	CcSEcCtD
Afatinib—Diarrhoea—Vinblastine—testicular cancer	0.000423	0.00207	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—testicular cancer	0.000423	0.00207	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—testicular cancer	0.000423	0.00206	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—testicular cancer	0.00042	0.00205	CcSEcCtD
Afatinib—Back pain—Etoposide—testicular cancer	0.000418	0.00204	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—testicular cancer	0.000416	0.00203	CcSEcCtD
Afatinib—ABCB1—testis—testicular cancer	0.000413	0.00345	CbGeAlD
Afatinib—Body temperature increased—Bleomycin—testicular cancer	0.000413	0.00202	CcSEcCtD
Afatinib—Dizziness—Vinblastine—testicular cancer	0.000409	0.002	CcSEcCtD
Afatinib—Nausea—Chlorambucil—testicular cancer	0.000401	0.00196	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000399	0.00195	CcSEcCtD
Afatinib—Dyspnoea—Ifosfamide—testicular cancer	0.000398	0.00194	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000398	0.0441	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000398	0.0441	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000398	0.0441	CbGdCrCtD
Afatinib—Vomiting—Vinblastine—testicular cancer	0.000393	0.00192	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—testicular cancer	0.000391	0.00191	CcSEcCtD
Afatinib—Decreased appetite—Ifosfamide—testicular cancer	0.000388	0.0019	CcSEcCtD
Afatinib—Headache—Vinblastine—testicular cancer	0.000388	0.00189	CcSEcCtD
Afatinib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000386	0.00188	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—testicular cancer	0.000385	0.00188	CcSEcCtD
Afatinib—Fatigue—Ifosfamide—testicular cancer	0.000385	0.00188	CcSEcCtD
Afatinib—Infection—Cisplatin—testicular cancer	0.000383	0.00187	CcSEcCtD
Afatinib—Constipation—Ifosfamide—testicular cancer	0.000382	0.00187	CcSEcCtD
Afatinib—Nervous system disorder—Cisplatin—testicular cancer	0.000378	0.00184	CcSEcCtD
Afatinib—Cough—Etoposide—testicular cancer	0.000377	0.00184	CcSEcCtD
Afatinib—Asthenia—Bleomycin—testicular cancer	0.000375	0.00183	CcSEcCtD
Afatinib—Dehydration—Epirubicin—testicular cancer	0.000374	0.00183	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—testicular cancer	0.000374	0.00183	CcSEcCtD
Afatinib—Pruritus—Bleomycin—testicular cancer	0.00037	0.00181	CcSEcCtD
Afatinib—Dry skin—Epirubicin—testicular cancer	0.000369	0.0018	CcSEcCtD
Afatinib—Nausea—Vinblastine—testicular cancer	0.000368	0.00179	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—testicular cancer	0.000366	0.00179	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000365	0.00178	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000362	0.00177	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—testicular cancer	0.00036	0.00176	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000355	0.00173	CcSEcCtD
Afatinib—Body temperature increased—Ifosfamide—testicular cancer	0.000353	0.00172	CcSEcCtD
Afatinib—Infection—Etoposide—testicular cancer	0.000351	0.00171	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—testicular cancer	0.00035	0.00171	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—testicular cancer	0.000346	0.00169	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000345	0.00169	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—testicular cancer	0.000343	0.00168	CcSEcCtD
Afatinib—Skin disorder—Etoposide—testicular cancer	0.000343	0.00167	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—testicular cancer	0.000341	0.00167	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—testicular cancer	0.000339	0.00165	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000335	0.00164	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—testicular cancer	0.000335	0.00163	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—testicular cancer	0.000334	0.00163	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—testicular cancer	0.000333	0.00163	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—testicular cancer	0.000333	0.00163	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000332	0.00162	CcSEcCtD
Afatinib—Vomiting—Bleomycin—testicular cancer	0.000332	0.00162	CcSEcCtD
Afatinib—Infestation—Methotrexate—testicular cancer	0.000331	0.00162	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—testicular cancer	0.000331	0.00162	CcSEcCtD
Afatinib—Rash—Bleomycin—testicular cancer	0.00033	0.00161	CcSEcCtD
Afatinib—Dermatitis—Bleomycin—testicular cancer	0.000329	0.00161	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000328	0.0016	CcSEcCtD
Afatinib—Renal failure—Methotrexate—testicular cancer	0.000326	0.00159	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000323	0.00158	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—testicular cancer	0.000323	0.00158	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—testicular cancer	0.000322	0.00157	CcSEcCtD
Afatinib—Asthenia—Ifosfamide—testicular cancer	0.00032	0.00156	CcSEcCtD
Afatinib—Pruritus—Ifosfamide—testicular cancer	0.000316	0.00154	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—testicular cancer	0.000315	0.00154	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—testicular cancer	0.000315	0.00154	CcSEcCtD
Afatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000314	0.0018	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—HPGDS—testicular cancer	0.000313	0.0018	CbGpPWpGaD
Afatinib—Hepatobiliary disease—Methotrexate—testicular cancer	0.000313	0.00153	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—testicular cancer	0.000313	0.00153	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—testicular cancer	0.000312	0.00152	CcSEcCtD
Afatinib—EGFR—Downstream signal transduction—KITLG—testicular cancer	0.000311	0.00179	CbGpPWpGaD
Afatinib—Nausea—Bleomycin—testicular cancer	0.00031	0.00152	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—testicular cancer	0.00031	0.00151	CcSEcCtD
Afatinib—Infestation—Epirubicin—testicular cancer	0.00031	0.00151	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—testicular cancer	0.00031	0.00151	CcSEcCtD
Afatinib—EGFR—Signaling by FGFR—KITLG—testicular cancer	0.00031	0.00178	CbGpPWpGaD
Afatinib—EGFR—PI3K/AKT activation—KIT—testicular cancer	0.000309	0.00177	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—KITLG—testicular cancer	0.000308	0.00177	CbGpPWpGaD
Afatinib—Rash—Dactinomycin—testicular cancer	0.000307	0.0015	CcSEcCtD
Afatinib—EGFR—DAP12 signaling—KITLG—testicular cancer	0.000307	0.00176	CbGpPWpGaD
Afatinib—Decreased appetite—Etoposide—testicular cancer	0.000307	0.0015	CcSEcCtD
Afatinib—EGFR—GAB1 signalosome—KIT—testicular cancer	0.000306	0.00176	CbGpPWpGaD
Afatinib—Diarrhoea—Ifosfamide—testicular cancer	0.000306	0.00149	CcSEcCtD
Afatinib—Renal failure—Epirubicin—testicular cancer	0.000305	0.00149	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000305	0.00149	CcSEcCtD
Afatinib—LCK—PI-3K cascade—KIT—testicular cancer	0.000305	0.00175	CbGpPWpGaD
Afatinib—Body temperature increased—Cisplatin—testicular cancer	0.000304	0.00149	CcSEcCtD
Afatinib—Fatigue—Etoposide—testicular cancer	0.000304	0.00149	CcSEcCtD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000302	0.00173	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—FGFR3—testicular cancer	0.000302	0.00173	CbGpPWpGaD
Afatinib—Stomatitis—Epirubicin—testicular cancer	0.000302	0.00148	CcSEcCtD
Afatinib—Constipation—Etoposide—testicular cancer	0.000302	0.00147	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—testicular cancer	0.000301	0.00147	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—testicular cancer	0.000301	0.00147	CcSEcCtD
Afatinib—EPHA6—Axon guidance—MMP2—testicular cancer	0.000301	0.00172	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—KITLG—testicular cancer	0.0003	0.00172	CbGpPWpGaD
Afatinib—ABCB1—lymph node—testicular cancer	0.0003	0.0025	CbGeAlD
Afatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000299	0.00172	CbGpPWpGaD
Afatinib—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000299	0.00146	CcSEcCtD
Afatinib—LCK—Signaling by FGFR—KITLG—testicular cancer	0.000299	0.00171	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—FGFR3—testicular cancer	0.000298	0.00171	CbGpPWpGaD
Afatinib—LCK—PI3K/AKT activation—KIT—testicular cancer	0.000297	0.0017	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—KITLG—testicular cancer	0.000297	0.0017	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—INSL3—testicular cancer	0.000297	0.0017	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—KITLG—testicular cancer	0.000296	0.0017	CbGpPWpGaD
Afatinib—Dizziness—Ifosfamide—testicular cancer	0.000295	0.00144	CcSEcCtD
Afatinib—LCK—GAB1 signalosome—KIT—testicular cancer	0.000295	0.00169	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—KITLG—testicular cancer	0.000294	0.00169	CbGpPWpGaD
Afatinib—Urinary tract disorder—Methotrexate—testicular cancer	0.000294	0.00143	CcSEcCtD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000294	0.00168	CbGpPWpGaD
Afatinib—Hepatobiliary disease—Epirubicin—testicular cancer	0.000293	0.00143	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—testicular cancer	0.000292	0.00143	CcSEcCtD
Afatinib—ERBB4—Signaling Pathways—INSL3—testicular cancer	0.000292	0.00168	CbGpPWpGaD
Afatinib—Urethral disorder—Methotrexate—testicular cancer	0.000292	0.00142	CcSEcCtD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000291	0.00167	CbGpPWpGaD
Afatinib—Weight decreased—Doxorubicin—testicular cancer	0.000291	0.00142	CcSEcCtD
Afatinib—Nausea—Dactinomycin—testicular cancer	0.00029	0.00141	CcSEcCtD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000289	0.00166	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—KITLG—testicular cancer	0.000289	0.00166	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	0.000289	0.00166	CbGpPWpGaD
Afatinib—Pneumonia—Doxorubicin—testicular cancer	0.000289	0.00141	CcSEcCtD
Afatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000288	0.00165	CbGpPWpGaD
Afatinib—Infestation NOS—Doxorubicin—testicular cancer	0.000287	0.0014	CcSEcCtD
Afatinib—Infestation—Doxorubicin—testicular cancer	0.000287	0.0014	CcSEcCtD
Afatinib—EGFR—Signaling by EGFR—KITLG—testicular cancer	0.000286	0.00164	CbGpPWpGaD
Afatinib—Vomiting—Ifosfamide—testicular cancer	0.000284	0.00139	CcSEcCtD
Afatinib—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000284	0.00163	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—KITLG—testicular cancer	0.000282	0.00162	CbGpPWpGaD
Afatinib—Renal failure—Doxorubicin—testicular cancer	0.000282	0.00138	CcSEcCtD
Afatinib—Rash—Ifosfamide—testicular cancer	0.000282	0.00138	CcSEcCtD
Afatinib—Dermatitis—Ifosfamide—testicular cancer	0.000281	0.00137	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—testicular cancer	0.00028	0.00137	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—testicular cancer	0.000279	0.00136	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—testicular cancer	0.000279	0.00136	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—testicular cancer	0.000279	0.00136	CcSEcCtD
Afatinib—LCK—Signaling by FGFR in disease—KITLG—testicular cancer	0.000278	0.0016	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—KITLG—testicular cancer	0.000278	0.0016	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000278	0.0016	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—BCL10—testicular cancer	0.000278	0.00159	CbGpPWpGaD
Afatinib—Eye disorder—Methotrexate—testicular cancer	0.000278	0.00136	CcSEcCtD
Afatinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000278	0.00159	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—KIT—testicular cancer	0.000278	0.00159	CbGpPWpGaD
Afatinib—Asthenia—Cisplatin—testicular cancer	0.000276	0.00135	CcSEcCtD
Afatinib—LCK—Signaling by EGFR—KITLG—testicular cancer	0.000276	0.00158	CbGpPWpGaD
Afatinib—Urinary tract disorder—Epirubicin—testicular cancer	0.000275	0.00134	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—testicular cancer	0.000274	0.00134	CcSEcCtD
Afatinib—PHKG2—Disease—H2AFZ—testicular cancer	0.000273	0.00157	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—KIT—testicular cancer	0.000273	0.00157	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000273	0.00157	CbGpPWpGaD
Afatinib—Urethral disorder—Epirubicin—testicular cancer	0.000273	0.00133	CcSEcCtD
Afatinib—LCK—Signaling by PDGF—KITLG—testicular cancer	0.000272	0.00156	CbGpPWpGaD
Afatinib—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000271	0.00132	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—testicular cancer	0.000271	0.00132	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—testicular cancer	0.000268	0.00131	CcSEcCtD
Afatinib—EGFR—B Cell Activation—KITLG—testicular cancer	0.000267	0.00153	CbGpPWpGaD
Afatinib—Nausea—Ifosfamide—testicular cancer	0.000265	0.0013	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—testicular cancer	0.000263	0.00129	CcSEcCtD
Afatinib—Alopecia—Methotrexate—testicular cancer	0.000263	0.00128	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—testicular cancer	0.000261	0.00127	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—testicular cancer	0.00026	0.00127	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—testicular cancer	0.000259	0.00126	CcSEcCtD
Afatinib—LCK—B Cell Activation—KITLG—testicular cancer	0.000257	0.00148	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000257	0.00148	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000256	0.00147	CbGpPWpGaD
Afatinib—Urinary tract disorder—Doxorubicin—testicular cancer	0.000254	0.00124	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—testicular cancer	0.000254	0.00124	CcSEcCtD
Afatinib—Asthenia—Etoposide—testicular cancer	0.000253	0.00124	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000253	0.00124	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—testicular cancer	0.000252	0.00123	CcSEcCtD
Afatinib—PHKG2—Disease—KITLG—testicular cancer	0.000252	0.00144	CbGpPWpGaD
Afatinib—Mediastinal disorder—Epirubicin—testicular cancer	0.000251	0.00122	CcSEcCtD
Afatinib—Back pain—Methotrexate—testicular cancer	0.00025	0.00122	CcSEcCtD
Afatinib—Pruritus—Etoposide—testicular cancer	0.00025	0.00122	CcSEcCtD
Afatinib—LCK—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000248	0.00142	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000246	0.00141	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000246	0.00141	CbGpPWpGaD
Afatinib—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000246	0.00141	CbGpPWpGaD
Afatinib—Alopecia—Epirubicin—testicular cancer	0.000246	0.0012	CcSEcCtD
Afatinib—Vomiting—Cisplatin—testicular cancer	0.000245	0.0012	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—testicular cancer	0.000244	0.00119	CcSEcCtD
Afatinib—Rash—Cisplatin—testicular cancer	0.000243	0.00119	CcSEcCtD
Afatinib—EGFR—Signaling by GPCR—INSL3—testicular cancer	0.000243	0.00139	CbGpPWpGaD
Afatinib—Dermatitis—Cisplatin—testicular cancer	0.000243	0.00118	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—testicular cancer	0.000242	0.00118	CcSEcCtD
Afatinib—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	0.000242	0.00139	CbGpPWpGaD
Afatinib—Diarrhoea—Etoposide—testicular cancer	0.000241	0.00118	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—testicular cancer	0.000241	0.00118	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—testicular cancer	0.000237	0.00116	CcSEcCtD
Afatinib—LCK—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000237	0.00136	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	0.000236	0.00135	CbGpPWpGaD
Afatinib—Back pain—Epirubicin—testicular cancer	0.000234	0.00114	CcSEcCtD
Afatinib—LCK—Signaling by ERBB4—FGFR3—testicular cancer	0.000234	0.00134	CbGpPWpGaD
Afatinib—Dizziness—Etoposide—testicular cancer	0.000233	0.00114	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—testicular cancer	0.000233	0.00114	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000232	0.00113	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—KITLG—testicular cancer	0.000232	0.00133	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—FGFR3—testicular cancer	0.000231	0.00133	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—FGFR3—testicular cancer	0.00023	0.00132	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	0.000229	0.00131	CbGpPWpGaD
Afatinib—Nausea—Cisplatin—testicular cancer	0.000229	0.00112	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—KITLG—testicular cancer	0.000228	0.00131	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—FGFR3—testicular cancer	0.000228	0.00131	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—STK11—testicular cancer	0.000228	0.00131	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—KIT—testicular cancer	0.000228	0.00131	CbGpPWpGaD
Afatinib—Alopecia—Doxorubicin—testicular cancer	0.000228	0.00111	CcSEcCtD
Afatinib—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000226	0.0013	CbGpPWpGaD
Afatinib—Cough—Methotrexate—testicular cancer	0.000226	0.0011	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—testicular cancer	0.000226	0.0011	CcSEcCtD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000225	0.00129	CbGpPWpGaD
Afatinib—Vomiting—Etoposide—testicular cancer	0.000224	0.0011	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—testicular cancer	0.000224	0.00109	CcSEcCtD
Afatinib—ERBB2—Immune System—BCL10—testicular cancer	0.000224	0.00128	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000223	0.00128	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—FGFR3—testicular cancer	0.000223	0.00128	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KITLG—testicular cancer	0.000223	0.00128	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—MMP2—testicular cancer	0.000223	0.00128	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—KIT—testicular cancer	0.000222	0.00128	CbGpPWpGaD
Afatinib—Rash—Etoposide—testicular cancer	0.000222	0.00109	CcSEcCtD
Afatinib—Dermatitis—Etoposide—testicular cancer	0.000222	0.00109	CcSEcCtD
Afatinib—LCK—Signaling by FGFR—FGFR3—testicular cancer	0.000222	0.00127	CbGpPWpGaD
Afatinib—Headache—Etoposide—testicular cancer	0.000221	0.00108	CcSEcCtD
Afatinib—LCK—Signaling by ERBB2—FGFR3—testicular cancer	0.000221	0.00127	CbGpPWpGaD
Afatinib—ERBB4—Immune System—BCL10—testicular cancer	0.000221	0.00127	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—FGFR3—testicular cancer	0.00022	0.00126	CbGpPWpGaD
Afatinib—Dysgeusia—Doxorubicin—testicular cancer	0.00022	0.00107	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—KITLG—testicular cancer	0.000219	0.00126	CbGpPWpGaD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000219	0.00107	CcSEcCtD
Afatinib—IRAK1—Signaling by NGF—FGFR3—testicular cancer	0.000219	0.00125	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000218	0.00125	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—BCL10—testicular cancer	0.000218	0.00125	CbGpPWpGaD
Afatinib—Back pain—Doxorubicin—testicular cancer	0.000217	0.00106	CcSEcCtD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000217	0.00124	CbGpPWpGaD
Afatinib—Muscle spasms—Doxorubicin—testicular cancer	0.000216	0.00105	CcSEcCtD
Afatinib—EPHA6—Developmental Biology—MMP2—testicular cancer	0.000215	0.00123	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—FGFR3—testicular cancer	0.000215	0.00123	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000215	0.00123	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000215	0.00123	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—INSL3—testicular cancer	0.000214	0.00123	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—KIT—testicular cancer	0.000214	0.00123	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—FGFR3—testicular cancer	0.000213	0.00122	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—KIT—testicular cancer	0.000212	0.00122	CbGpPWpGaD
Afatinib—BLK—Immune System—BCL10—testicular cancer	0.000212	0.00122	CbGpPWpGaD
Afatinib—Cough—Epirubicin—testicular cancer	0.000211	0.00103	CcSEcCtD
Afatinib—EGFR—Signaling by FGFR—KIT—testicular cancer	0.000211	0.00121	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—KITLG—testicular cancer	0.000211	0.00121	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000211	0.00121	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—MMP2—testicular cancer	0.000211	0.00121	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—KIT—testicular cancer	0.00021	0.00121	CbGpPWpGaD
Afatinib—Infection—Methotrexate—testicular cancer	0.00021	0.00103	CcSEcCtD
Afatinib—EGFR—Signaling by PDGF—FGFR3—testicular cancer	0.00021	0.0012	CbGpPWpGaD
Afatinib—Nausea—Etoposide—testicular cancer	0.00021	0.00102	CcSEcCtD
Afatinib—EGFR—DAP12 signaling—KIT—testicular cancer	0.000209	0.0012	CbGpPWpGaD
Afatinib—Nervous system disorder—Methotrexate—testicular cancer	0.000207	0.00101	CcSEcCtD
Afatinib—LCK—DAP12 interactions—FGFR3—testicular cancer	0.000207	0.00119	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000207	0.00119	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000207	0.00119	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000206	0.00118	CbGpPWpGaD
Afatinib—Skin disorder—Methotrexate—testicular cancer	0.000205	0.001	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000205	0.001	CcSEcCtD
Afatinib—LCK—Signaling by EGFR—FGFR3—testicular cancer	0.000205	0.00117	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—KIT—testicular cancer	0.000205	0.00117	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000204	0.00117	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—KIT—testicular cancer	0.000204	0.00117	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000203	0.00116	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—KIT—testicular cancer	0.000203	0.00116	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—FGFR3—testicular cancer	0.000202	0.00116	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—KIT—testicular cancer	0.000202	0.00116	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—KIT—testicular cancer	0.000201	0.00115	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000199	0.00114	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—FGFR3—testicular cancer	0.000199	0.00114	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	0.000197	0.00113	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000197	0.00113	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—KIT—testicular cancer	0.000197	0.00113	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KITLG—testicular cancer	0.000197	0.00113	CbGpPWpGaD
Afatinib—Infection—Epirubicin—testicular cancer	0.000196	0.000959	CcSEcCtD
Afatinib—Cough—Doxorubicin—testicular cancer	0.000196	0.000955	CcSEcCtD
Afatinib—EGFR—Signaling by EGFR—KIT—testicular cancer	0.000195	0.00112	CbGpPWpGaD
Afatinib—Nervous system disorder—Epirubicin—testicular cancer	0.000194	0.000947	CcSEcCtD
Afatinib—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000193	0.00111	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—KIT—testicular cancer	0.000193	0.0011	CbGpPWpGaD
Afatinib—Skin disorder—Epirubicin—testicular cancer	0.000192	0.000938	CcSEcCtD
Afatinib—LCK—B Cell Activation—FGFR3—testicular cancer	0.000191	0.0011	CbGpPWpGaD
Afatinib—Insomnia—Methotrexate—testicular cancer	0.000191	0.000933	CcSEcCtD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00019	0.00109	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—KIT—testicular cancer	0.00019	0.00109	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—KIT—testicular cancer	0.00019	0.00109	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00019	0.00109	CbGpPWpGaD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00019	0.000926	CcSEcCtD
Afatinib—LCK—Signaling by NGF—KITLG—testicular cancer	0.000189	0.00109	CbGpPWpGaD
Afatinib—Dyspnoea—Methotrexate—testicular cancer	0.000188	0.00092	CcSEcCtD
Afatinib—LCK—Signaling by EGFR—KIT—testicular cancer	0.000188	0.00108	CbGpPWpGaD
Afatinib—PHKG2—Disease—FGFR3—testicular cancer	0.000187	0.00107	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000186	0.00107	CbGpPWpGaD
Afatinib—Dyspepsia—Methotrexate—testicular cancer	0.000186	0.000908	CcSEcCtD
Afatinib—EGFR—Innate Immune System—BCL10—testicular cancer	0.000186	0.00107	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—KIT—testicular cancer	0.000186	0.00106	CbGpPWpGaD
Afatinib—Decreased appetite—Methotrexate—testicular cancer	0.000184	0.000897	CcSEcCtD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000183	0.00105	CbGpPWpGaD
Afatinib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000182	0.000891	CcSEcCtD
Afatinib—EGFR—B Cell Activation—KIT—testicular cancer	0.000182	0.00105	CbGpPWpGaD
Afatinib—Fatigue—Methotrexate—testicular cancer	0.000182	0.00089	CcSEcCtD
Afatinib—Infection—Doxorubicin—testicular cancer	0.000182	0.000888	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—testicular cancer	0.000179	0.000876	CcSEcCtD
Afatinib—LCK—Innate Immune System—BCL10—testicular cancer	0.000179	0.00103	CbGpPWpGaD
Afatinib—Insomnia—Epirubicin—testicular cancer	0.000179	0.000873	CcSEcCtD
Afatinib—EGFR—Adaptive Immune System—BCL10—testicular cancer	0.000179	0.00102	CbGpPWpGaD
Afatinib—Skin disorder—Doxorubicin—testicular cancer	0.000178	0.000868	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—testicular cancer	0.000176	0.000861	CcSEcCtD
Afatinib—LCK—B Cell Activation—KIT—testicular cancer	0.000176	0.00101	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000174	0.001	CbGpPWpGaD
Afatinib—Dyspepsia—Epirubicin—testicular cancer	0.000174	0.00085	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—FGFR3—testicular cancer	0.000172	0.000989	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—BCL10—testicular cancer	0.000172	0.000987	CbGpPWpGaD
Afatinib—Decreased appetite—Epirubicin—testicular cancer	0.000172	0.000839	CcSEcCtD
Afatinib—PHKG2—Disease—KIT—testicular cancer	0.000172	0.000985	CbGpPWpGaD
Afatinib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000171	0.000834	CcSEcCtD
Afatinib—Fatigue—Epirubicin—testicular cancer	0.000171	0.000833	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—FGFR3—testicular cancer	0.00017	0.000974	CbGpPWpGaD
Afatinib—Constipation—Epirubicin—testicular cancer	0.000169	0.000826	CcSEcCtD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000168	0.000964	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KITLG—testicular cancer	0.000168	0.000962	CbGpPWpGaD
Afatinib—Body temperature increased—Methotrexate—testicular cancer	0.000167	0.000816	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—FGFR3—testicular cancer	0.000166	0.000949	CbGpPWpGaD
Afatinib—Insomnia—Doxorubicin—testicular cancer	0.000166	0.000808	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—testicular cancer	0.000163	0.000797	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—FGFR3—testicular cancer	0.000163	0.000935	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BCL10—testicular cancer	0.000162	0.000929	CbGpPWpGaD
Afatinib—Dyspepsia—Doxorubicin—testicular cancer	0.000161	0.000786	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—testicular cancer	0.000159	0.000777	CcSEcCtD
Afatinib—ERBB2—Developmental Biology—MMP2—testicular cancer	0.000159	0.000911	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—KIT—testicular cancer	0.000158	0.000908	CbGpPWpGaD
Afatinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000158	0.000771	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—testicular cancer	0.000158	0.00077	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—FGFR3—testicular cancer	0.000157	0.0009	CbGpPWpGaD
Afatinib—Constipation—Doxorubicin—testicular cancer	0.000156	0.000764	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—testicular cancer	0.000156	0.000763	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—KIT—testicular cancer	0.000156	0.000894	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KIT—testicular cancer	0.000152	0.000872	CbGpPWpGaD
Afatinib—Asthenia—Methotrexate—testicular cancer	0.000152	0.00074	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—KIT—testicular cancer	0.00015	0.000859	CbGpPWpGaD
Afatinib—Pruritus—Methotrexate—testicular cancer	0.00015	0.00073	CcSEcCtD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000148	0.00085	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—FGFR3—testicular cancer	0.000146	0.000838	CbGpPWpGaD
Afatinib—Body temperature increased—Doxorubicin—testicular cancer	0.000145	0.000706	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—testicular cancer	0.000145	0.000706	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—KIT—testicular cancer	0.000144	0.000826	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INSL3—testicular cancer	0.000143	0.000822	CbGpPWpGaD
Afatinib—Asthenia—Epirubicin—testicular cancer	0.000142	0.000693	CcSEcCtD
Afatinib—LCK—Signaling by NGF—FGFR3—testicular cancer	0.000141	0.000808	CbGpPWpGaD
Afatinib—Pruritus—Epirubicin—testicular cancer	0.00014	0.000683	CcSEcCtD
Afatinib—Dizziness—Methotrexate—testicular cancer	0.00014	0.000682	CcSEcCtD
Afatinib—LCK—Signaling Pathways—INSL3—testicular cancer	0.000138	0.000793	CbGpPWpGaD
Afatinib—ERBB2—Disease—H2AFZ—testicular cancer	0.000136	0.000778	CbGpPWpGaD
Afatinib—Diarrhoea—Epirubicin—testicular cancer	0.000135	0.000661	CcSEcCtD
Afatinib—ERBB2—Immune System—KITLG—testicular cancer	0.000135	0.000775	CbGpPWpGaD
Afatinib—Vomiting—Methotrexate—testicular cancer	0.000134	0.000656	CcSEcCtD
Afatinib—EGFR—Signaling by NGF—KIT—testicular cancer	0.000134	0.000769	CbGpPWpGaD
Afatinib—ERBB4—Disease—H2AFZ—testicular cancer	0.000134	0.000766	CbGpPWpGaD
Afatinib—Rash—Methotrexate—testicular cancer	0.000133	0.000651	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—testicular cancer	0.000133	0.00065	CcSEcCtD
Afatinib—ERBB4—Immune System—KITLG—testicular cancer	0.000133	0.000763	CbGpPWpGaD
Afatinib—Headache—Methotrexate—testicular cancer	0.000132	0.000646	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—testicular cancer	0.000131	0.000641	CcSEcCtD
Afatinib—ABL1—Innate Immune System—KITLG—testicular cancer	0.000131	0.000753	CbGpPWpGaD
Afatinib—Dizziness—Epirubicin—testicular cancer	0.000131	0.000639	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—testicular cancer	0.000129	0.000632	CcSEcCtD
Afatinib—LCK—Signaling by NGF—KIT—testicular cancer	0.000129	0.000741	CbGpPWpGaD
Afatinib—BLK—Immune System—KITLG—testicular cancer	0.000128	0.000734	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL10—testicular cancer	0.000127	0.000727	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP2—testicular cancer	0.000126	0.000722	CbGpPWpGaD
Afatinib—Vomiting—Epirubicin—testicular cancer	0.000126	0.000614	CcSEcCtD
Afatinib—Nausea—Methotrexate—testicular cancer	0.000126	0.000613	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—testicular cancer	0.000125	0.000611	CcSEcCtD
Afatinib—ERBB2—Disease—KITLG—testicular cancer	0.000125	0.000715	CbGpPWpGaD
Afatinib—Rash—Epirubicin—testicular cancer	0.000125	0.000609	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—FGFR3—testicular cancer	0.000125	0.000715	CbGpPWpGaD
Afatinib—Dermatitis—Epirubicin—testicular cancer	0.000125	0.000608	CcSEcCtD
Afatinib—Headache—Epirubicin—testicular cancer	0.000124	0.000605	CcSEcCtD
Afatinib—ERBB4—Disease—KITLG—testicular cancer	0.000123	0.000705	CbGpPWpGaD
Afatinib—Dizziness—Doxorubicin—testicular cancer	0.000121	0.000591	CcSEcCtD
Afatinib—Nausea—Epirubicin—testicular cancer	0.000117	0.000574	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—testicular cancer	0.000116	0.000568	CcSEcCtD
Afatinib—Rash—Doxorubicin—testicular cancer	0.000115	0.000563	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—testicular cancer	0.000115	0.000563	CcSEcCtD
Afatinib—Headache—Doxorubicin—testicular cancer	0.000115	0.00056	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—KIT—testicular cancer	0.000114	0.000656	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KITLG—testicular cancer	0.000112	0.000643	CbGpPWpGaD
Afatinib—Nausea—Doxorubicin—testicular cancer	0.000109	0.000531	CcSEcCtD
Afatinib—EGFR—Immune System—BCL10—testicular cancer	0.000108	0.000621	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KITLG—testicular cancer	0.000108	0.00062	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KITLG—testicular cancer	0.000108	0.000618	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP2—testicular cancer	0.000108	0.000617	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL10—testicular cancer	0.000104	0.000599	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KITLG—testicular cancer	0.000104	0.000595	CbGpPWpGaD
Afatinib—ERBB2—Immune System—FGFR3—testicular cancer	0.0001	0.000576	CbGpPWpGaD
Afatinib—ERBB4—Immune System—FGFR3—testicular cancer	9.89e-05	0.000567	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KITLG—testicular cancer	9.77e-05	0.00056	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—FGFR3—testicular cancer	9.75e-05	0.000559	CbGpPWpGaD
Afatinib—BLK—Immune System—FGFR3—testicular cancer	9.51e-05	0.000546	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—H2AFZ—testicular cancer	9.5e-05	0.000545	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STK11—testicular cancer	9.44e-05	0.000541	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—H2AFZ—testicular cancer	9.35e-05	0.000536	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STK11—testicular cancer	9.3e-05	0.000533	CbGpPWpGaD
Afatinib—ERBB2—Disease—FGFR3—testicular cancer	9.27e-05	0.000532	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KIT—testicular cancer	9.22e-05	0.000529	CbGpPWpGaD
Afatinib—ERBB4—Disease—FGFR3—testicular cancer	9.13e-05	0.000524	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KIT—testicular cancer	9.08e-05	0.000521	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP2—testicular cancer	8.99e-05	0.000515	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KIT—testicular cancer	8.96e-05	0.000514	CbGpPWpGaD
Afatinib—BLK—Immune System—KIT—testicular cancer	8.74e-05	0.000501	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KITLG—testicular cancer	8.74e-05	0.000501	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KITLG—testicular cancer	8.6e-05	0.000493	CbGpPWpGaD
Afatinib—ERBB2—Disease—KIT—testicular cancer	8.51e-05	0.000488	CbGpPWpGaD
Afatinib—ERBB4—Disease—KIT—testicular cancer	8.38e-05	0.000481	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—FGFR3—testicular cancer	8.33e-05	0.000478	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—FGFR3—testicular cancer	8.03e-05	0.000461	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	8e-05	0.000459	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	7.71e-05	0.000442	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP2—testicular cancer	7.68e-05	0.00044	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KIT—testicular cancer	7.65e-05	0.000439	CbGpPWpGaD
Afatinib—ABL1—Immune System—KITLG—testicular cancer	7.64e-05	0.000438	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KIT—testicular cancer	7.37e-05	0.000423	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KIT—testicular cancer	7.35e-05	0.000421	CbGpPWpGaD
Afatinib—IRAK1—Immune System—FGFR3—testicular cancer	7.26e-05	0.000416	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KIT—testicular cancer	7.08e-05	0.000406	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HPGDS—testicular cancer	7.01e-05	0.000402	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	6.87e-05	0.000394	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STK11—testicular cancer	6.83e-05	0.000391	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KIT—testicular cancer	6.67e-05	0.000382	CbGpPWpGaD
Afatinib—EGFR—Disease—H2AFZ—testicular cancer	6.56e-05	0.000376	CbGpPWpGaD
Afatinib—EGFR—Immune System—KITLG—testicular cancer	6.53e-05	0.000375	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FGFR3—testicular cancer	6.49e-05	0.000372	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FGFR3—testicular cancer	6.4e-05	0.000367	CbGpPWpGaD
Afatinib—LCK—Disease—H2AFZ—testicular cancer	6.32e-05	0.000362	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	6.32e-05	0.000362	CbGpPWpGaD
Afatinib—LCK—Immune System—KITLG—testicular cancer	6.29e-05	0.000361	CbGpPWpGaD
Afatinib—EGFR—Disease—KITLG—testicular cancer	6.03e-05	0.000346	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KIT—testicular cancer	5.96e-05	0.000342	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KIT—testicular cancer	5.87e-05	0.000337	CbGpPWpGaD
Afatinib—LCK—Disease—KITLG—testicular cancer	5.81e-05	0.000333	CbGpPWpGaD
Afatinib—ABL1—Immune System—FGFR3—testicular cancer	5.68e-05	0.000326	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIT—testicular cancer	5.22e-05	0.000299	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—STK11—testicular cancer	5.1e-05	0.000292	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGFR3—testicular cancer	4.85e-05	0.000278	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	4.69e-05	0.000269	CbGpPWpGaD
Afatinib—LCK—Immune System—FGFR3—testicular cancer	4.68e-05	0.000268	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	4.59e-05	0.000263	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STK11—testicular cancer	4.56e-05	0.000262	CbGpPWpGaD
Afatinib—EGFR—Disease—FGFR3—testicular cancer	4.48e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—Immune System—KIT—testicular cancer	4.46e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	4.42e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STK11—testicular cancer	4.4e-05	0.000252	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR3—testicular cancer	4.32e-05	0.000248	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KIT—testicular cancer	4.31e-05	0.000247	CbGpPWpGaD
Afatinib—LCK—Immune System—KIT—testicular cancer	4.3e-05	0.000246	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KITLG—testicular cancer	4.22e-05	0.000242	CbGpPWpGaD
Afatinib—EGFR—Disease—KIT—testicular cancer	4.12e-05	0.000236	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KITLG—testicular cancer	4.07e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—Disease—KIT—testicular cancer	3.97e-05	0.000227	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HPGDS—testicular cancer	3.79e-05	0.000217	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR3—testicular cancer	3.14e-05	0.00018	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR3—testicular cancer	3.02e-05	0.000173	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—testicular cancer	2.88e-05	0.000165	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—testicular cancer	2.78e-05	0.000159	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—testicular cancer	2.76e-05	0.000158	CbGpPWpGaD
